Boston Scientific ( BSX) will likely close its deal to acquire medical-device maker Guidant ( GDT) a bit later than expected, resulting in millions of dollars in interest payments. For each day the closing is delayed, Boston will tack on 1.32 cents a share in cash, amounting to about $4.5 million a day. According to its January agreement to acquire Guidant for $80 a share, Boston set an expected closing date of March 31 and said it would pay interest each day that the deal was delayed. Boston now sees the $27 billion takeover closing during the week of April 3, according to documents filed with the Securities and Exchange Commission Wednesday. Stockholders of both companies will vote on the merger March 31. Boston attributed the expected delay to customary closing conditions, including obtaining antitrust clearance. Additionally, shareholders have to approve an agreement in which Abbott ( ABT), a drug and device company, will acquire Guidant's vascular intervention business. Boston Scientific won Guidant after prevailing in an intense bidding war with Johnson & Johnson ( JNJ). J&J's last offer was $71 a share, a price it wouldn't exceed in the wake of Guidant's recall of tens of thousands of its implanted heart devices last year. Shares of Boston were down 48 cents, or 2%, to $23.52. Guidant was unchanged at $77.07.